Verrica Pharmaceuticals Inc. Operating Income Loss

• Verrica Pharmaceuticals Inc. showed an increase of +81.5% in Operating Income Loss from 2024 to 2025.
• This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Verrica Pharmaceuticals Inc.'s Operating Income Loss has declined by 173.4%.
• Historical annual values: Fiscal year 2025: -$12.19 million | Fiscal year 2024: -$65.92 million | Fiscal year 2023: -$65.76 million | Fiscal year 2022: -$21.30 million | Fiscal year 2021: -$30.91 million | Fiscal year 2020: -$40.18 million | Fiscal year 2019: -$30.08 million | Fiscal year 2018: -$21.88 million | Fiscal year 2017: -$4.46 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026